StockData
USANA Health Sciences Inc logo

USANA Health Sciences Inc (USNA) stock analysis

USNANYSEMedicinal Chemicals & Botanical ProductsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Oct 3, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3061% below fair value
$12.85−0.25 (-1.91%)

Close on Nov 11, 2026Market cap $237.42MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value4Growth0Performance2Health5Dividend0

Mixed11 of 30 checks passed

USANA Health Sciences passes 11 of the 30 checks behind our score; 7 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
4/6
Growth
0/6
Past performance
2/6
Financial health
5/6
Dividend
0/6

What stands out

  • Margin of safety over 20%

    The price is 60.5% below fair value, more than the 20% cushion we look for.

  • Trading below fair value

    The share price of $12.85 is below our fair value estimate of $32.54.

  • No debt

    USANA Health Sciences has no borrowings on its latest balance sheet.

  • Debt covered by cash flow

    There is no debt to cover.

What to watch

  • Return on equity under 15%

    Return on equity was -4.2% over the last twelve months and averaged 13.7% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -0.1%, below the 10% that usually covers the cost of capital.

  • Earnings shrank over 5 years

    Net income shrank 38.7% a year on average over the last five fiscal years.

  • Revenue growing under 10% a year

    Revenue grew -2.5% a year over the last three fiscal years, short of the 10% we look for.

Valuation4/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA below its 5-year median

    USANA Health Sciences's EV/EBITDA of 2.2 is below its 5-year median of 5.4.

  • P/B below the industry

    USANA Health Sciences's price-to-book of 0.45 is below the Drugs median of 2.29.

  • Trading below fair value

    The share price of $12.85 is below our fair value estimate of $32.54.

  • Margin of safety over 20%

    The price is 60.5% below fair value, more than the 20% cushion we look for.

Growth0/6

  • Revenue growing under 10% a year

    Revenue grew -2.5% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -45.5% a year over the last three fiscal years.

  • Earnings growth not accelerating

    Net income grew -165% over the last twelve months, against a 5-year average of -38.7% a year.

  • Growing slower than the industry

    Revenue grew 1.6% over the last twelve months; the Drugs median is 8.0%.

  • Guidance lowered

    USANA Health Sciences lowered its fiscal year 2026 Net (loss) earnings outlook on Nov 3, 2026.

  • Gross margin slipping

    Gross margin was 77.4% over the last twelve months, against 79.9% a year earlier.

Past performance2/6

  • Return on equity under 15%

    Return on equity was -4.2% over the last twelve months and averaged 13.7% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -0.1%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    USANA Health Sciences's return on equity of -4.2% is above the Drugs median of -58.9%.

  • Earnings shrank over 5 years

    Net income shrank 38.7% a year on average over the last five fiscal years.

  • Net margin below its 5-year average

    Net margin was -2.4% over the last twelve months, against a 5-year average of 6.0%.

  • Net margin above the industry

    USANA Health Sciences's net margin of -2.4% is above the Drugs median of -53.0%.

Financial health5/6

  • No debt

    USANA Health Sciences has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest not well covered

    Operating income covers interest expense -2.6 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 2.66 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 3.57; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    USANA Health Sciences has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$32.54

The share price is 61% below this estimate.

20%+ below
Near fair value
20%+ above
$12.85Price$32.54Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
EV/EBITDA11.2×5.4×17.1×$28.1258%
P/B2.0×1.8×2.3×$57.6717%
Earnings power8.1% cost of equity––$26.1125%
Fair value$32.54100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 15.2
  • Drugs median 25.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Medium risk

Average value traded per day
$2.80M
Value traded per 1% price move
$1.45M

Downside

High risk

Typical loss in a bad month
39.7%
Volatility (annualized)
53%
Sharpe ratio, 1 year
-0.70
Beta to the S&P 500 (5Y)
0.65

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

78.3%−3.3 pts over 5 years

Operating margin

4.0%−11.5 pts over 5 years

Net margin

1.2%−9.8 pts over 5 years

See a number that looks wrong?